Variability in Individual Responsiveness to Clopidogrel

Fuster, 1990, Atherosclerotic plaque rupture and thrombosis, Circulation, 82, II47 Storey, 2001, Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood, Platelets, 12, 443, 10.1080/09537100120085450 Schomig, 1996, A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents, N Engl J Med, 334, 1084, 10.1056/NEJM199604253341702 Leon, 1998, A clinical trial comparing three antithrombotic drug regimens after coronary-artery stenting, N Engl J Med, 339, 1665, 10.1056/NEJM199812033392303 Bertrand, 1998, Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting, Circulation, 98, 1597, 10.1161/01.CIR.98.16.1597 Urban, 1998, Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS), Circulation, 98, 2126, 10.1161/01.CIR.98.20.2126 Bertrand, 2000, Circulation, 102, 624, 10.1161/01.CIR.102.6.624 Smith, 2006, J Am Coll Cardiol, 47, e1, 10.1016/j.jacc.2005.12.001 Mehta, 2001, Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study, Lancet, 358, 527, 10.1016/S0140-6736(01)05701-4 Steinhubl, 2002, Clopidogrel for the Reduction of Events During Observation, JAMA, 288, 2411, 10.1001/jama.288.19.2411 Yusuf, 2001, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N Engl J Med, 345, 494, 10.1056/NEJMoa010746 Sabatine, 2005, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation, N Engl J Med, 352, 1179, 10.1056/NEJMoa050522 Chen, 2005, Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial, Lancet, 366, 1607, 10.1016/S0140-6736(05)67660-X Savi, 2005, Clopidogrel and ticlopidine: P2Y12adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis, Semin Thromb Hemost, 31, 174, 10.1055/s-2005-869523 Michelson, 2006, Current options in platelet function testing, Am J Cardiol, 98, S4, 10.1016/j.amjcard.2006.09.008 Frelinger, 2005, Clopidogrel linking evaluation of platelet response variability to mechanism of action, J Am Coll Cardiol, 46, 646, 10.1016/j.jacc.2005.05.039 Labarthe, 2005, Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug, J Am Coll Cardiol, 46, 638, 10.1016/j.jacc.2005.02.092 Aleil, 2005, Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases, J Thromb Haemost, 3, 85, 10.1111/j.1538-7836.2004.01063.x von Beckerath, 2006, Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness, Thromb Haemost, 95, 910, 10.1160/TH06-01-0046 Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity, Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 Muller, 2003, Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement, Thromb Haemost, 89, 783, 10.1055/s-0037-1613462 Angiolillo, 2005, Identification of low responders to a 300 mg clopidogrel loading dose in patients undergoing coronary stenting, Thromb Res, 115, 101, 10.1016/j.thromres.2004.07.007 Angiolillo, 2004, High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability, Eur Heart J, 25, 1903, 10.1016/j.ehj.2004.07.036 Samara, 2005, The difference between clopidogrel responsiveness and posttreatment platelet reactivity, Thromb Res, 115, 89, 10.1016/j.thromres.2004.07.002 Serebruany, 2005, Variability in platelet responsiveness to clopidogrel among 544 individuals, J Am Coll Cardiol, 45, 246, 10.1016/j.jacc.2004.09.067 Angiolillo, 2005, Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment, Diabetes, 54, 2430, 10.2337/diabetes.54.8.2430 Soffer, 2003, Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?, Catheter Cardiovasc Interv, 59, 21, 10.1002/ccd.10494 Angiolillo, 2004, Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?, J Invasive Cardiol, 16, 169 Angiolillo, 2006, Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment, J Am Coll Cardiol, 48, 298, 10.1016/j.jacc.2006.03.038 Taubert, 2004, Pharmacokinetics of clopidogrel after administration of a high loading dose, Thromb Haemost, 92, 311, 10.1160/TH04-02-0105 Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction, Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC Neubauer, 2003, Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function—a flow cytometry study, Eur Heart J, 24, 1744, 10.1016/S0195-668X(03)00442-1 Serebruany, 2004, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study, Arch Intern Med, 164, 2051, 10.1001/archinte.164.18.2051 Muller, 2003, Effects of statins on platelet inhibition by a high loading dose of clopidogrel, Circulation, 108, 2195, 10.1161/01.CIR.0000099507.32936.C0 Mitsios, 2004, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes, Circulation, 109, 1335, 10.1161/01.CIR.0000124581.18191.15 Gorchakova, 2004, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting, Eur Heart J, 25, 1898, 10.1016/j.ehj.2003.10.039 Angiolillo, 2007, Clopidogrel-statin interaction: myth or reality, J Am Coll Cardiol, 10.1016/j.jacc.2007.04.041 Lau, 2004, Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance, Circulation, 109, 166, 10.1161/01.CIR.0000112378.09325.F9 Angiolillo, 2006, Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel, Arterioscler Thromb Vasc Biol, 26, 1895, 10.1161/01.ATV.0000223867.25324.1a Beitelshees, 2006, Clopidogrel pharmacogenetics: promising steps towards patient care?, Arterioscler Thromb Vasc Biol, 26, 1681, 10.1161/01.ATV.0000232583.51472.73 Fontana, 2003, Adenosine diphosphate-induced platelet aggregation is associated with P2Y12gene sequence variations in healthy subjects, Circulation, 108, 989, 10.1161/01.CIR.0000085073.69189.88 von Beckerath, 2005, P2Y12gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose, Blood Coagul Fibrinolysis, 16, 199, 10.1097/01.mbc.0000164429.21040.0a Angiolillo, 2005, Lack of association between the P2Y12receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease, Thromb Res, 116, 491, 10.1016/j.thromres.2005.03.001 Lev, 2007, Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel, Thromb Res, 119, 355, 10.1016/j.thromres.2006.02.006 Angiolillo, 2004, PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation, Blood Coagul Fibrinolysis, 15, 89, 10.1097/00001721-200401000-00014 Cooke, 2006, Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination, J Am Coll Cardiol, 47, 541, 10.1016/j.jacc.2005.09.034 Angiolillo, 2004, Polymorphisms of the GP IIIa and P2Y12receptors and modulation of antiplatelet effects of combined aspirin and clopidogrel treatment, Circulation, 110, 2013 Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052 Smith, 2006, Common sequence variations in the P2Y12and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy, Platelets, 17, 250, 10.1080/09537100500475844 Angiolillo, 2004, 807 C/T polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment, Blood Coagul Fibrinolysis, 15, 427, 10.1097/01.mbc.0000114439.81125.86 Angiolillo, 2005, Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene, Am J Cardiol, 96, 1095, 10.1016/j.amjcard.2005.06.039 Angiolillo, 2006, Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention, Am J Cardiol, 97, 38, 10.1016/j.amjcard.2005.07.106 Barragan, 2003, Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation, Catheter Cardiovasc Interv, 59, 295, 10.1002/ccd.10497 Ajzenberg, 2005, Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study, J Am Coll Cardiol, 45, 1753, 10.1016/j.jacc.2004.10.079 Gurbel, 2005, Clopidogrel effects on platelet reactivity in patients with stent thrombosis, J Am Coll Cardiol, 46, 1827, 10.1016/j.jacc.2005.07.056 Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction, Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 Cuisset, 2006, High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome, J Thromb Haemost, 4, 542, 10.1111/j.1538-7836.2005.01751.x Cuisset, 2006, Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non–ST-segment elevation acute coronary syndrome undergoing coronary stenting, J Am Coll Cardiol, 48, 1339, 10.1016/j.jacc.2006.06.049 Hochholzer, 2006, Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement, J Am Coll Cardiol, 48, 1742, 10.1016/j.jacc.2006.06.065 Gurbel, 2005, Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study, Circulation, 111, 1153, 10.1161/01.CIR.0000157138.02645.11 Gurbel, 2006, The effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results of the CLEAR PLATELETS-Ib study, J Am Coll Cardiol, 48, 2186, 10.1016/j.jacc.2005.12.084 Gurbel, 2005, Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study, J Am Coll Cardiol, 46, 1820, 10.1016/j.jacc.2005.07.041 Bliden, 2007, Increased risk in patients with high platelet aggregation on chronic clopidogrel therapy undergoing PCI: is the current antiplatelet therapy adequate?, J Am Coll Cardiol, 49, 657, 10.1016/j.jacc.2006.10.050 Lev, 2006, Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance, J Am Coll Cardiol, 47, 27, 10.1016/j.jacc.2005.08.058 Geisler, 2006, Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation, Eur Heart J, 27, 2420, 10.1093/eurheartj/ehl275 Wiviott, 2004, Clopidogrel resistance: a new chapter in a fast-moving story, Circulation, 109, 3064, 10.1161/01.CIR.0000134701.40946.30 Gurbel, 2005, The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting, J Am Coll Cardiol, 45, 1392, 10.1016/j.jacc.2005.01.030 Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention, Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98 Patti, 2005, Circulation, 111, 2099, 10.1161/01.CIR.0000161383.06692.D4 von Beckerath, 2005, Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 Montalescot, 2006, A randomized comparison of high clopidogrel loading-doses in patients with non–ST-elevation acute coronary syndromes: the ALBION trial, J Am Coll Cardiol, 48, 931, 10.1016/j.jacc.2006.04.090 Dalby, 2004, Eptifibatide provides additional platelet inhibition in non–ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel, J Am Coll Cardiol, 43, 162, 10.1016/j.jacc.2003.08.033 Kastrati, 2004, Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy, Circulation, 110, 1916, 10.1161/01.CIR.0000137972.74120.12 Thebault, 1999, Repeated-dose pharmacodynamics of clopidogrel in healthy subjects, Semin Thromb Hemost, 25, 9 von Beckerath, 2006, A double-blind randomized comparison between two different clopidogrel maintenance doses after percutaneous coronary intervention (ISAR-CHOICE 2 Trial), Eur Heart J, 27, 5039 Angiolillo, 2007, Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study, Circulation, 115, 708, 10.1161/CIRCULATIONAHA.106.667741 Angiolillo, 2007, ADP receptor antagonism: what’s in the pipeline?, Am J Cardiovasc Drugs, 10.2165/00129784-200707060-00005 Niitsu, 2005, Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12receptor antagonist activity, Semin Thromb Hemost, 31, 184, 10.1055/s-2005-869524 Brandt, 2007, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation, Am Heart J, 153, e9, 10.1016/j.ahj.2006.10.010 Jernberg, 2006, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease, Eur Heart J, 27, 1166, 10.1093/eurheartj/ehi877 Wiviott, 2005, Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial, Circulation, 111, 3366, 10.1161/CIRCULATIONAHA.104.502815 van Giezen, 2005, Preclinical and clinical studies with selective reversible direct P2Y12antagonists, Semin Thromb Hemost, 31, 195, 10.1055/s-2005-869525 Husted, 2006, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin, Eur Heart J, 27, 1038, 10.1093/eurheartj/ehi754 Cannon, 2005, The DISPERSE 2 Trial: safety, tolerability and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non–ST-segment elevation acute coronary syndrome, Circulation, 112, 615 Greenbaum, 2006, Initial experience with an intravenous P2Y12platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial, Am Heart J, 151, 689, 10.1016/j.ahj.2005.11.014 Alfonso, 2006, Platelet function assessment to predict outcomes after coronary interventions: hype or hope?, J Am Coll Cardiol, 48, 1751, 10.1016/j.jacc.2006.08.009